Clinical Trial Update: JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating JAB-21822 in combination with cetuximab for KRAS G12C-mutant advanced colorectal cancer and other solid tumors; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Appendiceal Cancer
• Colorectal Cancer
• Small Intestinal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• JAB-21822

Snippet

Sponsor: Allist Pharmaceuticals, Inc. | Conditions: Advanced Colorectal Cancer, Small Intestinal Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING